The HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24(1):123-137. PMCID: PMC2920287
The HIV-CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce rates of mortality and AIDS in HIV-infected individuals in developed countries. Annals of Internal Medicine 2011; 154(8):504-515. PMCID: PMC3610527
The HIV-CAUSAL Collaboration. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 2012; 26(13): 1691-1705. PMCID: PMC3647467. Reply and additional results. AIDS 2013; 27:2169–2172.
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, Del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration. Antiretroviral penetration into the central nervous system and the incidence of AIDS-defining neurological conditions. Neurology 2014; 83(2):134-141. PMCID: PMC4117168. Correspondence in Neurology 2015;84(2).
The HIV-CAUSAL Collaboration. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. AIDS 2014; 28(16):2461-73. PMCID: PMC4495885
The HIV-CAUSAL Collaboration. Boosted lopinavir vs. boosted atazanavir-containing regimens and immunologic, virologic and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries. Clinical Infectious Diseases 2015; 60(8): 1262-1268. PMCID: PMC4447777
The HIV-CAUSAL Collaboration. Comparative effectiveness of strategies for antiretroviral treatment initiation in HIV-positive individuals in high-income countries: immediate universal treatment versus CD4-based initiation. Lancet HIV 2015; 2(8):e335-343. PMCID: PMC4643831
Caniglia EC, Sabin C, Robins JM, Logan R, Cain LE, Abgrall S, Mugavero MJ, Hernandez-Diaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RR, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Olson A, Justice AC, Tate JP, Bucher HC, Egger M, Touloumi G, Sterne JA, Costagliola D, Saag M, Hernán MA; Center for AIDS Research Network of Integrated Clinical Systems and the HIV-CAUSAL Collaboration. When to monitor CD4 cell count and HIV RNA to reduce mortality and AIDS-defining illness in virologically suppressed HIV-positive persons on antiretroviral therapy in high-income countries: a prospective observational study. Journal of the Acquired Immune Deficiency Syndromes 2016; 72(2):214-221. PMCID: PMC4866894
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall Sophie, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende M-A, Logan R, Robins JM, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA, on behalf of the HIV-CAUSAL Collaboration. Efavirenz vs. boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-positive individuals. Medicine 2016; 95(41): e5133. PMCID: PMC5072966
Caniglia EC, Cain LE, Sabin CA, Robins JM, Logan R, Abgrall S, Mugavero MJ, Hernández-Díaz S, Meyer L, Seng R, Drozd DR, Seage GR 3rd, Bonnet F, Dabis F, Moore RD, Reiss P, van Sighem A, Mathews WC, Del Amo J, Moreno S, Deeks SG, Muga R, Boswell SL, Ferrer E, Eron JJ, Napravnik S, Jose S, Phillips A, Justice AC, Tate JP, Gill J, Pacheco A, Veloso VG, Bucher HC, Egger M, Furrer H, Porter K, Touloumi G, Crane H, Miro JM, Sterne JA, Costagliola D, Saag M, Hernán MA, on behalf of the HIV-CAUSAL Collaboration and the Centers for AIDS Research Network of Integrated Clinical Systems. Comparing dynamic monitoring strategies based on evolving CD4 cell counts in virologically suppressed HIV-positive individuals on cART: a prospective observational study in high-income countries. Lancet HIV 2017; 4:e251-259. PMCID: PMC5492888
Lodi S, Costagliola D, Sabin C, Amo JD, Logan R, Abgrall S, Reiss P, van Sighem A, Jose S, Blanco JR, Hernando V, Bucher HC, Kovari H, Segura F, Ambrosioni J, Gogos CA, Pantazis N, Dabis F, Vandenhende MA, Meyer L, Seng R, Gill J, Krentz H, Phillips A, Porter K, Grinsztejn B, Pacheco AG, Muga R, Tate J, Justice A, Hernán MA. Effect of immediate initiation of antiretroviral treatment in HIV-positive individuals aged 50 years or older. Journal of Acquired Immune Deficiency Syndromes 2017; 76(3):311-318. PMCID: PMC5704899
Lodi S, Günthard HF, Dunn D, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Schneider MP, Egger M, Glass TR, Reiss P, van Sighem A, Boender TS, Phillips AN, Porter K, Hawkins D, Moreno S, Monge S, Paraskevis D, Simeon M, Vourli G, Sabin C, Hernán MA; HIV-CAUSAL Collaboration. Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. AIDS 2018; 32(3):327-355. PMCID: PMC5758415
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA; HIV-CAUSAL Collaboration. Commonly prescribed antiretroviral therapy regimens and incidence of AIDS-defining neurological conditions. Journal of Acquired Immunodeficiency Syndromes 2018; 77(1):102-109. PMCID: PMC5720915
Lodi S, Günthard HF, Gill J, Phillips AN, Dunn D, Vu Q, Siemieniuk R, Garcia F, Logan R, Jose S, Bucher HC, Scherrer AU, Reiss P, van Sighem A, Boender TS, Porter K, Gilson R, Paraskevis D, Simeon M, Vourli G, Moreno S, Jarrin I, Sabin C, Hernán MA. Effectiveness of transmitted drug resistance testing before initiation of antiretroviral therapy in HIV-positive individuals. Journal of Acquired Immune Deficiency Syndromes 2019; 82(3): 314-320. PMCID: PMC7830777
Rein SM, Lodi S, Logan RW, Touloumi G, Antoniadou A, Wittkop L, Bonnet F, van Sighem A, van der Valk M, Reiss P, Klein MB, Young J, Jarrin I, d’Arminio Monforte A, Tavelli A, Meyer L, Tran L, Gill MJ, Lang R, Surial B, Haas AD, Justice AC, Rentsch CT, Phillips A, Sabin CA, Miro JM, Trickey A, Ingle SM, Sterne JAC, Hernán MA; Antiretroviral Therapy Cohort Collaboration and the HIV-CAUSAL Collaboration. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration. Lancet HIV. 2023 Nov;10(11):e723-e732. doi: 10.1016/S2352-3018(23)00233-3. PMID: 37923486; PMCID: PMC10695103.
Collaborations with Pediatric HIV cohorts
Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd, for the Pediatric AIDS Clinical Trials Group 219/219C Study Team. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clinical Infectious Diseases 2008; 46(4):507-515.
Caniglia E, Patel K, Huo Y, Kapetanovic S, Rich K, Sirois P, Williams P, Hernán MA, Seage G, for the Pediatric HIV/AIDS Cohort. Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study. AIDS 2016; 30(8): 1267-1278. PMCID: PMC4851579
Caniglia EC, Zash R, Jacobson DL, Diseko M, Mayondi G, Lockman S, Chen J, Mmalane M, Makhema J, Hernán MA, Shapiro RL. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes in an era of CD4-based treatment initiation. AIDS 2018; 32(1):113-120. PMCID: PMC5718935
Collaborations with African HIV cohorts
Franke MF, Robins JM, Mugabo J, Kaigamba F, Cain LE, Fleming JG, Murray MB. Effectiveness of Early Antiretroviral Therapy Initiation to Improve Survival among a Cohort of HIV-Infected Adults with Tuberculosis Disease. PLoS Medicine 2011;8(5):e1001029. PMCID:PMC3086874
Fox MP, van Cutsem G, Giddy J, Maskew M, Keiser O, Prozes0ky H, Wood R, Hernán MA, Sterne JAC, Egger M, Boulle A, for the IeDEA-SA collaboration. Rates and predictors of failure of first-line antiretroviral therapy and switch to second-line ART in South Africa. Journal of Acquired Immunodeficiency Syndromes 2012; 60(4): 428-437. PMCID: PMC3392418
Luque-Fernández MA, Van Cutsem G, Goemaere E, Hilderbrand K, Schomaker M, Mantangana N, Mathee S, Dubula V, Hernán MA, Boulle A. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS ONE 2013; 8(2):e56088. PMCID:PMC3571960
